Study design for development of novel safety biomarkers of drug-induced liver injury by the translational safety biomarker pipeline (TransBioLine) consortium: a study protocol for a nested case–control study

A lack of biomarkers that detect drug-induced liver injury (DILI) accurately continues to hinder early- and late-stage drug development and remains a challenge in clinical practice. The Innovative Medicines Initiative’s TransBioLine consortium comprising academic and industry partners is developing...

Descripción completa

Detalles Bibliográficos
Autores principales: Grove, Jane I., Stephens, Camilla, Lucena, M. Isabel, Andrade, Raúl J., Weber, Sabine, Gerbes, Alexander, Bjornsson, Einar S., Stirnimann, Guido, Daly, Ann K., Hackl, Matthias, Khamina-Kotisch, Kseniya, Marin, Jose J. G., Monte, Maria J., Paciga, Sara A., Lingaya, Melanie, Forootan, Shiva S., Goldring, Christopher E. P., Poetz, Oliver, Lombaard, Rudolf, Stege, Alexandra, Bjorrnsson, Helgi K., Robles-Diaz, Mercedes, Li, Dingzhou, Tran, Thi Dong Binh, Ramaiah, Shashi K., Samodelov, Sophia L., Kullak-Ublick, Gerd A., Aithal, Guruprasad P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10496294/
https://www.ncbi.nlm.nih.gov/pubmed/37697410
http://dx.doi.org/10.1186/s41512-023-00155-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10496294/
https://www.ncbi.nlm.nih.gov/pubmed/37697410
http://dx.doi.org/10.1186/s41512-023-00155-z

Ejemplares similares